|Name:||Methyldopa||Synonyms:||;L-A-METHYL DOPA MK-351, METHYLDOPA;MethyldopaUsp28/Bp2003/Ep5;3-Hydroxy-α-methyl-L-tyrosine;L-Tyrosine, 3-hydroxy-.alpha.-methyl-;2-METHYL-3-(3,4-DIHYDROXYPHENYL)ALANINE|
|Cas No:||555-30-6||Ec No:||209-089-2|
|Molecular Formula:||C10H13NO4||Molecular Weight:||211.22|
|Melting Point:||≥300 °C||Boiling Point:||350.89°C|
555-30-6 Alpha Methyldopa Api Receptor Dopamine,
Cas 555 30-6 Alpha Methyldopa Api Dopamine,
alpha methyldopa api dopamine receptors 555-30-6
|Synonyms||;L-A-METHYL DOPA MK-351, METHYLDOPA;MethyldopaUsp28/Bp2003/Ep5;3-Hydroxy-α-methyl-L-tyrosine;L-Tyrosine, 3-hydroxy-.alpha.-methyl-;2-METHYL-3-(3,4-DIHYDROXYPHENYL)ALANINE|
|CAS Registry Number||555-30-6|
|Melting point||≥300 °C|
Methyldopa is an α-methoxylated derivative of levodopa that exhibits hypotensive action by reducing overall peripheral vascular resistance and reducing heart work. Antihypertensive action of methyldopa consists of the biotransformation of methyldopa into methylnoradrenaline (methylnorepinephrine), which acts as a “pseudo neurotransmitter.” The current, universally accepted point of view is that the action of methyldopa is carried out through the CNS, where methylnorepinephrine, a powerful stimulant of α-adrenergic receptors of the medulla, inhibits the vasomotor center.
α-Methyldopa is not generally believed to be suitable for monotherapy of primary hypertension. Because plasma volume increases as the duration of α-methyldopa therapy is extended, the drug should be used in conjunction with a diuretic; this will produce a significantly greater fall in blood pressure than would occur with either drug used alone. Because α-methyldopa lowers blood pressure without compromising either renal blood flow or the glomerular filtration rate, it is particularly valuable in hypertension complicated by renal disease. However, if end-stage renal failure accompanies severe hypertension,α-methyldopa may not be effective.
The presence of α-methyldopa and its metabolites in the urine reduces the diagnostic value of urinary catecholamine measurements as an indicator of pheochromocytoma, since these substances interfere with the fluorescence assay for catecholamines.
|1||62-46-4||Alpha Lipoic Acid|
|12||128-13-2||Ursodeoxycholic Acid/ UDCA|